Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3235125 | 0.90 | HRH4 (0.68) | HRH4HRH3 | |
| SCHEMBL3260720 | 0.84 | HRH4 (0.54) | HRH4HRH3 | |
| SCHEMBL606703 | 0.84 | HRH4 (0.52) | HRH4HRH3ADRA1A | |
| SCHEMBL3233923 | 0.83 | HRH4 (0.61) | HRH4HRH3ADRA1A | |
| SCHEMBL3237073 | 0.83 | HRH4 (0.60) | HRH4HRH3 | |
| SCHEMBL3762900 | 0.79 | HRH4 (0.44) | HRH4HRH3ADRA1AAOC3 | |
| SCHEMBL3762897 | 0.79 | HRH4 (0.44) | HRH4HRH3ADRA1AAOC3 | |
| SCHEMBL606600 | 0.79 | HRH4 (0.48) | HRH4HRH3ADRA1A | |
| SCHEMBL603900 | 0.76 | HRH4 (0.47) | HRH4HRH3ADRA1A | |
| SCHEMBL3753365 | 0.75 | HRH4 (0.70) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2010-11-25 | — | — | US | claimed |
| EP-2209775-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB Pharma, S.A. (BE) | 2010-07-28 | — | — | EP | claimed |
| WO-2009047255-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2009-04-16 | — | — | WO | claimed |
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
| EP-2209775-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB Pharma, S.A. (BE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009047255-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | UCB PHARMA, S.A. (BE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298289-A1 | HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS | HRH4, HRH2, HRH3 | HRH4 1/4885HRH3 3/4885CNR2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.